Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2448-2455

  Bellone, Graziella ^a   Smirne, Carlo ^a   Carbone, Anna ^a   Mareschi, Katia ^a   Dughera, Luca ^a   Farina, Enzo C ^b   Alabiso, Oscar ^c   Valente, Guido ^c   Emanuelli, Giorgio ^a   Rodeck, Ulrich ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL VIABILITY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; PANCREAS CARCINOMA; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION;

ADULT; AGED; ANTIGENS, CD95; APOPTOSIS; CARCINOMA; CELL SEPARATION; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; JURKAT CELLS; LUMINESCENT PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0034099598     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J., 14: 1129-1135, 1995.
2. Dhein, J., Walczak, H., Baumler, C., Debatin, K. M., and Krammer, P. H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature (Lond.), 373: 438-441, 1995.
3. Brunner, T., Mogil, R. J., LaFace, D., Yoo, N. J., Mahboubi, A., Echeverri, F., Martin, S. J., Force, W. R., Lynch, D. H., Ware C. F., and Green, D. R. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (Lond.), 373: 441-444, 1995.
4. Ju, S. T., Panka, D. J., Cui, H., Ettinger, R., el-Khatib, M., Sherr, D. H., Stanger, B. Z., and Marshak-Rothstein, A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (Lond.), 373: 444-448, 1995.
5. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233-243, 1991.
6. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75: 1169-1178, 1993.
7. Enari, M., Hase, A., and Nagata, S. Apoptosis by a cytosolic extract from Fas-activated cells. EMBO J., 14: 5201-5208, 1995.
8. Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., Hatake, K., Drummond, A. H., and Nagata, S. Fas ligand in human serum. Nat. Med., 2: 317-322, 1996.
9. Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., and Galle, P. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med., 2: 1361-1366, 1996.
10. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
11. Gratas, C., Tohma, Y., Barnas, C., Taniere, P., Hainaut, P., and Ohgaki, H. Up-regulation of Fas (APO-1/CD95) ligand and downregulation of Fas expression in human esophageal cancer. Cancer Res., 58: 2057-2062, 1998.
12. Ungefroren, H., Voss, M., Jansen, M., Roeder, C., Henne-Bruns, D., Kremer, B., and Kalthoff, H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas mediated apoptosis. Cancer Res., 58: 1741-1749, 1998.
13. von Bernstorff, W., Spanjaard, R. A., Chan, A. K., Lockhart, D. C., Sadanaga, N., Wood, I., Peiper, M., Goedegebuure, P. S., and Eberlein, T. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery, 125: 73-84, 1999.
14. Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., and Yagita, H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med., 182: 1777-1783, 1995.
15. Liu, Q. Y., Rubin, M. A., Omene, C., Lederman, S., and Stein, C. A. Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res., 4: 1803-1811, 1998.
16. Tanaka, M., Itai, T., Adachi, M., and Nagata, S. Downregulation of Fas ligand by shedding. Nat. Med., 4: 31-36, 1998.
17. Schneider, P., Holler, N., Bodmer, J. L., Hahne, M., Frei, K., Fontana, A., and Tschopp, J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med., 187: 1205-1213, 1998.
18. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., and Mountz, J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science (Washington DC), 263: 1759-1762, 1994.
19. Lee, S. H., Kim, S. Y., Lee, J. Y., Shin, M. S., Dong, S. M., Na, E. Y., Park, W. S., Kim, K. M., Kim, C. S., Kim, S. H., and Yoo, N. J. Detection of soluble Fas mRNA using in situ reverse transcription-polymerase chain reaction. Lab. Investig., 78: 453-459, 1998.
20. Suda, T., Hashimoto, H., Tanaka, M., Ochi, T., and Nagata, S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med., 186: 2045-2050, 1997.
21. Warshaw, A. L., and Fernandez-del Castillo, C. Pancreatic carcinoma. N. Engl. J. Med., 326: 455-465, 1992.
22. Perussia, B., Ramoni, C., Anegon, I., Cuturi, M. C., Faust, J., and Trinchieri, G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat. Immun. Cell Growth Regul., 6: 171-188, 1987.
23. Bellone, G., Silvestri, S., Artusio, E., Tibaudi, D., Turletti, A., Geuna, M., Giachino, C., Valente, G., Emanuelli, G., and Rodeck, U. Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-β1. J. Cell. Physiol., 172: 1-11, 1997.
24. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
25. Bohm, C., Hanski, M. L., Gratchev, A., Mann, B., Moyer, M. P., Riecken, E. O., and Hanski, C. A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells. J. Immunol. Methods, 217: 71-78, 1998.
26. Matzinger, P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods, 145: 185-192, 1991.
27. Bellone, G., Astarita, P., Artusio, E., Silvestri, S., Mareschi, K., Turletti, A., Buttiglieri, S., Emanuelli, G., and Matera, L. Bone marrow stroma-derived prolactin is involved in basal and platelet-activating factor-stimulated in vitro erythropoiesis. Blood, 90: 21-27, 1997.
28. Mariani, S. M., Matiba, B., Baumler, C., and Krammer, P. H. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol., 25: 2303-2307, 1995.
29. Mitsiades, N., Poulaki, V., Kotoula, V., Leone, A., and Tsokos, M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am. J. Pathol., 153: 1947-1956, 1998.
30. von Reyher, U., Strater, J., Kittstein, W., Gschwendt, M., Krammer, P. H., and Moller, P. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res., 58: 526-534, 1998.
31. Kato, K., Ohshima, K., Ishihara, S., Anzai, K., Suzumiya, J., and Kikuchi, M. Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. Br. J. Haematol., 103: 1164-1166, 1998.
32. Yufu, Y., Choi, I., Hirase, N., Tokoro, A., Noguchi, Y., Goto, T., Uike, N., and Kozuru, M. Soluble Fas in the serum of patients with non-Hodgkin's lymphoma: higher concentrations in angioimmunoblastic T-cell lymphoma. Am. J. Hematol., 58: 334-336, 1998.
33. Jodo, S., Kobayashi, S., Nakajima, Y., Matsunaga, T., Nakayama, N., Ogura, N., Kayagaki, N., Okumura, K., and Koike, T. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin. Exp. Immunol., 112: 166-171, 1998.
34. Mizutani, Y., Yoshida, O., and Bonavida, B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J. Urol., 160: 571-576, 1998.
35. Cascino, I., Fiucci, G., Papoff, G., and Ruberti, G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol., 154: 2706-2713, 1995.
36. Papoff, G., Cascino, I., Eramo, A., Starace, G., Lynch, D. H., and Ruberti, G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol., 156: 4622-4630, 1996.
37. Martinez-Lorenzo, M. J., Alava, M. A., Anel, A., Pineiro, A., and Naval, J. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology, 89: 511-517, 1996.
38. Tschopp, J., Irmler, M., and Thome, M. Inhibition of Fas death signals by FLIPs. Curr. Opin. Immunol., 10: 552-558, 1998.
39. Sato, T., Irie, S., Kitada, S., and Reed, J. C. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science (Washington DC), 268: 411-415, 1995.